Cargando…

Blood-based biomarkers of cancer-related cognitive impairment in non-central nervous system cancer: protocol for a scoping review

INTRODUCTION: Cancer-related cognitive impairment (CRCI) can have detrimental effects on quality of life, even among patients with non-central nervous system (CNS) cancers. Several studies have been conducted to explore different markers associated with CRCI to understand its pathobiology. It is pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Mayo, Samantha J, Kuruvilla, John, Laister, Rob C, Ayala, Ana Patricia, Alm, Mark, Byker, Will, Kelly, Debra Lynch, Saligan, Leorey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5829658/
https://www.ncbi.nlm.nih.gov/pubmed/29374660
http://dx.doi.org/10.1136/bmjopen-2017-017578
_version_ 1783302853184454656
author Mayo, Samantha J
Kuruvilla, John
Laister, Rob C
Ayala, Ana Patricia
Alm, Mark
Byker, Will
Kelly, Debra Lynch
Saligan, Leorey
author_facet Mayo, Samantha J
Kuruvilla, John
Laister, Rob C
Ayala, Ana Patricia
Alm, Mark
Byker, Will
Kelly, Debra Lynch
Saligan, Leorey
author_sort Mayo, Samantha J
collection PubMed
description INTRODUCTION: Cancer-related cognitive impairment (CRCI) can have detrimental effects on quality of life, even among patients with non-central nervous system (CNS) cancers. Several studies have been conducted to explore different markers associated with CRCI to understand its pathobiology. It is proposed that the underlying mechanisms of CRCI are related to a cascade of physiological adaptive events in response to cancer and/or treatment. Hence, peripheral blood would be a logical source to observe and identify these physiological events. This paper outlines the protocol for a scoping review being conducted to summarise the extant literature regarding blood-based biomarkers of CRCI among patients with non-CNS cancer. METHODS/ANALYSIS: Methods will be informed by the updated guidelines of Arksey and O’Malley. The systematic search for literature will include electronic databases, handsearching of key journals and reference lists, forward citation tracking and consultation with content experts. Study selection will be confirmed by duplicate review and calculation of inter-rater reliability. Data to be charted will include study design, sample size, cancer and treatment characteristics, demographic characteristics, cognitive variable/s and biomarkers assessed, associations between cognitive functioning and biomarkers (including statistics used), and rigour in biomarker sample collection and processing. Results will be presented through: (1) a descriptive numerical summary of studies, including a flow diagram based on the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement, (2) a list of blood-based biomarkers associated with CRCI and (3) a narrative overview developed through collaboration among the research team and consultation with content experts. DISSEMINATION: The findings of this review will highlight current directions and gaps in the current body of evidence that may lead to improved rigour in future CRCI investigations. The dissemination of this work will be facilitated through the involvement of clinicians and researchers on the research team, an external consultation process and the presentation of the results through scholarly publication and presentation.
format Online
Article
Text
id pubmed-5829658
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-58296582018-03-05 Blood-based biomarkers of cancer-related cognitive impairment in non-central nervous system cancer: protocol for a scoping review Mayo, Samantha J Kuruvilla, John Laister, Rob C Ayala, Ana Patricia Alm, Mark Byker, Will Kelly, Debra Lynch Saligan, Leorey BMJ Open Oncology INTRODUCTION: Cancer-related cognitive impairment (CRCI) can have detrimental effects on quality of life, even among patients with non-central nervous system (CNS) cancers. Several studies have been conducted to explore different markers associated with CRCI to understand its pathobiology. It is proposed that the underlying mechanisms of CRCI are related to a cascade of physiological adaptive events in response to cancer and/or treatment. Hence, peripheral blood would be a logical source to observe and identify these physiological events. This paper outlines the protocol for a scoping review being conducted to summarise the extant literature regarding blood-based biomarkers of CRCI among patients with non-CNS cancer. METHODS/ANALYSIS: Methods will be informed by the updated guidelines of Arksey and O’Malley. The systematic search for literature will include electronic databases, handsearching of key journals and reference lists, forward citation tracking and consultation with content experts. Study selection will be confirmed by duplicate review and calculation of inter-rater reliability. Data to be charted will include study design, sample size, cancer and treatment characteristics, demographic characteristics, cognitive variable/s and biomarkers assessed, associations between cognitive functioning and biomarkers (including statistics used), and rigour in biomarker sample collection and processing. Results will be presented through: (1) a descriptive numerical summary of studies, including a flow diagram based on the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement, (2) a list of blood-based biomarkers associated with CRCI and (3) a narrative overview developed through collaboration among the research team and consultation with content experts. DISSEMINATION: The findings of this review will highlight current directions and gaps in the current body of evidence that may lead to improved rigour in future CRCI investigations. The dissemination of this work will be facilitated through the involvement of clinicians and researchers on the research team, an external consultation process and the presentation of the results through scholarly publication and presentation. BMJ Publishing Group 2018-01-27 /pmc/articles/PMC5829658/ /pubmed/29374660 http://dx.doi.org/10.1136/bmjopen-2017-017578 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Oncology
Mayo, Samantha J
Kuruvilla, John
Laister, Rob C
Ayala, Ana Patricia
Alm, Mark
Byker, Will
Kelly, Debra Lynch
Saligan, Leorey
Blood-based biomarkers of cancer-related cognitive impairment in non-central nervous system cancer: protocol for a scoping review
title Blood-based biomarkers of cancer-related cognitive impairment in non-central nervous system cancer: protocol for a scoping review
title_full Blood-based biomarkers of cancer-related cognitive impairment in non-central nervous system cancer: protocol for a scoping review
title_fullStr Blood-based biomarkers of cancer-related cognitive impairment in non-central nervous system cancer: protocol for a scoping review
title_full_unstemmed Blood-based biomarkers of cancer-related cognitive impairment in non-central nervous system cancer: protocol for a scoping review
title_short Blood-based biomarkers of cancer-related cognitive impairment in non-central nervous system cancer: protocol for a scoping review
title_sort blood-based biomarkers of cancer-related cognitive impairment in non-central nervous system cancer: protocol for a scoping review
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5829658/
https://www.ncbi.nlm.nih.gov/pubmed/29374660
http://dx.doi.org/10.1136/bmjopen-2017-017578
work_keys_str_mv AT mayosamanthaj bloodbasedbiomarkersofcancerrelatedcognitiveimpairmentinnoncentralnervoussystemcancerprotocolforascopingreview
AT kuruvillajohn bloodbasedbiomarkersofcancerrelatedcognitiveimpairmentinnoncentralnervoussystemcancerprotocolforascopingreview
AT laisterrobc bloodbasedbiomarkersofcancerrelatedcognitiveimpairmentinnoncentralnervoussystemcancerprotocolforascopingreview
AT ayalaanapatricia bloodbasedbiomarkersofcancerrelatedcognitiveimpairmentinnoncentralnervoussystemcancerprotocolforascopingreview
AT almmark bloodbasedbiomarkersofcancerrelatedcognitiveimpairmentinnoncentralnervoussystemcancerprotocolforascopingreview
AT bykerwill bloodbasedbiomarkersofcancerrelatedcognitiveimpairmentinnoncentralnervoussystemcancerprotocolforascopingreview
AT kellydebralynch bloodbasedbiomarkersofcancerrelatedcognitiveimpairmentinnoncentralnervoussystemcancerprotocolforascopingreview
AT saliganleorey bloodbasedbiomarkersofcancerrelatedcognitiveimpairmentinnoncentralnervoussystemcancerprotocolforascopingreview